

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla <i>et al.</i>	Confirmation No.: 1837
Serial No.: 10/806,295	Art Unit: 1617
Filed: March 22, 2004	Examiner: Cruz, Kathrien Ann
For: PHENYLINDOLES FOR THE TREATMENT OF HIV	Attorney Docket No: 11874-076-999 (CAM 417451-999076)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 AND 1.97

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

Documents A01-A05 are U.S. published patent applications and/or U.S. issued patents. Therefore, a copy of this reference is not being submitted pursuant to 37 C.F.R. §1.98(a)(2)(ii).

Copies of Documents B01-B04 and C01-C16 are submitted herewith.

Reference (B02) EP 0116360 A is a foreign language document. Pursuant to 37 C.F.R. § 1.98 (a)(3)(i) and (ii), Applicants direct the Examiner's attention to the abstract of related U.S. Patent No. 4,814,345, cited herein. The U.S. patent abstract describes 1-phenyl-2-aminocarbonylindole compounds.

Applicants respectfully request that the Examiner review the listed documents and that the documents be made of record in the file history of the application.

Identification of documents listed on the attached List of References Cited by Applicant is not to be construed as an admission of Applicants or attorneys for Applicants that such documents are available as "prior art" against the subject application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application. The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is to be charged to Jones Day deposit account no. 50-3013 (referencing 417451-999076).

The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Jones Day Deposit Account No. 50-3013 (order no. 417451-999076).

Respectfully submitted,

Date: March 20, 2009



Rahul Pathak

42,983

(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939